Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00631488 | A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015) | PHASE2 | COMPLETED | 146 | — | — | Feb 1, 2008 | Jan 1, 2009 | Jan 2, 2017 | - | — |
| Arm | Type | Description |
|---|---|---|
| MK-0893 + Sitagliptin | EXPERIMENTAL | - |
| MK-0893 + Metformin | EXPERIMENTAL | - |
| Sitagliptin + Metformin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| MK-0893 | DRUG | Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks). |
| Sitagliptin | DRUG | Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks). |
| Metformin | DRUG | Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks). |
| Placebo for MK-0893 | DRUG | Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period. |
| Placebo for Sitagliptin | DRUG | Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks). |
| Placebo for Metformin | DRUG | Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks). |
Inclusion Criteria: * Participants who have Type 2 Diabetes Mellitus, with suboptimal glucose control, while either not on AHA (antihyperglycemic agent) therapy or on monotherapy or on low-dose combination therapy Exclusion Criteria: * Participants have a history of Type 1 Diabetes Mellitus * Par...